Pages

▼
Tuesday, February 26, 2013

Functional Cure of Chronic Hepatitis B: RNAi Therapeutics May Be the Only Game in Town (Part I)

›
Today, I wanted to post the first of a two-part series on the hepatitis B virus (HBV) candidate by Arrowhead Research which is set to ent...
8 comments:
Friday, February 22, 2013

The RNAi Therapeutics Money is in the Product Candidates

›
If you believe, like I do, that the RNAi Therapeutics money ought  to be in delivery, the track record suggests that you are mistaken: ...
5 comments:
Sunday, February 17, 2013

RNAi Therapeutics, My Long View

›
Warning: disorganized thoughts gathered on a long plane ride.   Having followed the development of RNAi Therapeutics since it took off in...
23 comments:
Sunday, February 10, 2013

Is Alnylam Foolishly Betting the Farm on GalNAcs?

›
It is remarkable that Alnylam seems to be embracing GalNAc subcutaneous delivery for all pipeline candidates, but for perhaps ALN-TTR02, ...
8 comments:
Tuesday, February 5, 2013

Alnylam and The Medicines Company to Position RNAi PCSK9 Drug Candidate as Fast Follower

›
Yesterday, Alnylam made the somewhat surprising announcement that it partnered with the ~$1.6B market cap The Medicines Company to dev...
4 comments:
Thursday, January 31, 2013

ALN-VSP02 Was a Good Start, but Directs Focus Towards Improved Formulations

›
Alnylam recently published detailed phase I results from its RNAi Therapeutic candidate to treat liver cancer, ALN-VSP02.   Although r...
Wednesday, January 30, 2013

First Antisense Oligo Approved for Gene Knockdown in Liver

›
In a milestone for antisense oligonucleotide technology, Kynamro (aka mipomersen) yesterday received US regulatory approval for the t...